WAF1/cip1 plays a critical role in regulating intestinal cell proliferation, maturation and tumorigenesis. Our previous work demonstrated that inactivation of a single p21 allele in Apc1638 þ /À mice was sufficient to accelerate Apcinitiated tumor formation, and that inactivation of only one p21 allele was also sufficient to abrogate duodenal tumor inhibition by sulindac, a nonsteroidal anti-inflammatory drug. To dissect the role of p21 in sulindac inhibition of intestinal tumor development in Apc1638 þ /À mice, we quantified p21 expression from Apc
, p21 wildtype mice fed the sulindac supplemental diet, both p21 mRNA and protein were significantly increased in the flat mucosa and tumors of the duodenum. However, p21 was not induced by sulindac in the duodenal flat mucosa and tumors of Apc þ /À mice in which one or both p21 alleles had been inactivated. Further investigation revealed that the cytosine residues in a CpG cluster in the promoter region of the mouse p21 gene displayed hypermethylation in the Apc
þ /À mice. This suggested that although the p21 þ /À mice retained a wild-type allele, this allele was functionally modulated by hypermethylation, and that the inability of sulindac to inhibit tumor formation in Apc
þ /À mice is likely due to the inability to induce expression of the wild-type, but differentially methylated, p21 allele. Oncogene (2005) ; methylation Sulindac, a nonsteoridal anti-inflammatory drug (NSAID), has considerable activity as a chemopreventive agent for human colon cancer (Waddell et al., 1989; Labayle et al., 1991; Giardiello et al., 1993; Nugent et al., 1993) . The activity of sulindac in inhibition of intestinal tumorigenesis is recapitulated in mouse models in which tumors are initiated by the targeting of the Apc gene (Boolbol et al., 1996; Yang et al., 2001b) . The mechanism by which sulindac inhibits intestinal tumor formation has been strongly linked to the ability of sulindac to inhibit expression of the enzyme COX2, the form of cyclooxygenase that is specifically elevated in intestinal tumor cells, but not expressed in the normal colonic mucosa (Shiff and Rigas, 1997; Subbaramaiah et al., 1997) . However, there is also evidence that the action of sulindac may be through effects other than those on COX2 (Soh and Weinstein, 2003) . Regardless of whether the inhibition of COX2 by sulindac is necessary for tumor inhibition, we presented evidence that the cyclin-dependent kinase (cdk) p21 WAF1/cip1 is a key factor in the ability of sulindac to inhibit intestinal tumorigenesis. First, we confirmed a previous report (Goldberg et al., 1996) that sulindac induced p21 levels in colon carcinoma cells in vitro, and also showed by microarray analysis that treatment of human subjects daily for 1 month with sulindac elevated p21 mRNA expression in biopsies of the rectal mucosa (Yang et al., 2001b) . In fact, p21 was one of only 0.1% of the 9000 sequences assayed, which responded similarly to sulindac both in vitro and in vivo. We then used a genetic approach to demonstrate the necessity of p21 expression for response to sulindac, in that the introduction of a targeted inactivation of p21 into Apc1638
À/À mice) abrogated the ability of sulindac to inhibit tumor formation in the duodenum initiated by the loss of Apc function (Yang et al., 2001b) . This importance of p21 in tumorigenesis is consistent with the fact that the gene is normally expressed in the intestinal mucosa coincident with exit of cells from the proliferative compartment as they migrate up the crypt (el-Deiry et al., 1995; Polyak et al., 1996; Gartel and Tyner, 1999) , and that p21 plays a fundamental role in lineage-specific differentiation of intestinal epithelial cells, as well as in their cell cycle arrest (Yang et al., 2001a; van de Wetering et al., 2002) .
It was, however, unexpected that duodenal tumor formation was not inhibited by sulindac in Apc1638
þ /À mice, since we assumed that these mice retained a wild-type p21 allele that could be induced by sulindac. In this report, therefore, we have investigated the induction of p21 by sulindac in the Apc
and À/À mice, and its association with methylation of C residues in CpG sequences upstream of the start site of transcription of the mouse p21 gene.
We first assayed the level of p21 expression in the mouse models. Figure 1 illustrates that p21 mRNA is expressed in both the duodenal mucosa ( Figure 1a ) and duodenal tumors (Figure 1b) of Apc
þ / þ mice when they were maintained on control AIN-76A diet, as determined by quantitative real-time PCR. As expected, on the control diet, lower expression of p21 mRNA was seen in both the mucosa and tumors in the Apc
þ / À mice, and no expression was detected in the Apc
À/À mice (Figure 1a and b) . Figure 1 also shows that feeding the animals a diet supplemented with sulindac was effective in elevating p21 mRNA expression approximately threefold in both the mucosa (P ¼ 0.037, Student's t-test) and in the tumors
þ / þ mice, confirming our previous data from microarray analysis (Yang et al., 2001b) . Again, as expected, the targeted inactivation of both p21 alleles in Apc
À/À mice resulted in no induction of p21 mRNA expression by sulindac. However, in the Apc
þ /À mice, while basal expression of p21 mRNA was maintained at about 50% of the level detected in p21 þ / þ mice, there was no induction of p21 in either the mucosa or the tumors in the sulindac-fed animals compared to those fed the control diet. Figure 1c extends the experiments to the analysis of p21 protein, with similar results. In Apc
þ / þ mice, sulindac in the diet induced the expression of p21 protein in both the flat mucosa and in duodenal tumors. By scanning densitometry, this induction was approximately 3.5-fold. However, in the Apc
þ /À mice, there was no induction by sulindac ( Figure 1c ). There was no expression or induction of p21 protein in Apc
The homologous recombination that targeted p21 for inactivation eliminated exon 2 (Deng et al., 1995) . Since our quantitative RT-PCR primers targeted these eliminated sequences, and since the p21 protein in the Apc
þ /À mice was of the same molecular weight as the wild-type protein, it is clear that these analyses of expression specifically assayed the wild-type allele. Thus, it was possible that clonal selection during tumor growth eliminated the wild-type p21 allele in the tumors of Apc þ /À , p21 þ /À mice, leading to the absence of induction by sulindac. However, it was highly unlikely that the wild-type allele was lost in the mucosa in general. In fact, PCR analysis of duodenal and tumor DNA demonstrated the presence of the allele in both the mucosa and the tumors of Apc 
þ /À mice, assayed by quantitative real-time RT-PCR. A similar result was seen for p21 WAF1 protein expression (c). As reported (Yang et al., 2001a, b) , the mouse model was generated by mating Apc1638 þ /À mice with p21
þ / À offspring (F1), and these F1 mice then mated to generate F2 mice that were Apc þ /À and either p21
Mice were randomized to either AIN-76A diet (Harlan-Teklad) or AIN-76A containing 0.02% sulindac and killed after 36 weeks. Total RNA and protein were isolated from the frozen tissues using TRIzol reagent (Invitrogen Life Technology, Carlsbad, CA, USA), as described (Yang et al., 2003) . cDNA was synthesized from Dnase-treated total RNA using TaqMan Multiscribe Reverse Transcriptase (Applied Biosystems, Inc., Foster City, CA, USA) and quantitative PCR analysis performed using the ABI Prism 7900-HT Sequence Detection System (96-well), as described (Yang et al., 2003) . The following primers were used: b-actin, forward 5 0 -ACCCACACTGTGCC-CATCTAC-3 0 and reverse 5 0 -GCCATCTCCTGCTCGAAGTC-3 0 ; p21 WAF1/cip1 , forward 5 0 -GACAGTGAGCAGTTGCG-3 0 and reverse 5 0 -CTCAGACACCAGAGTGC-3 0 . Protein levels were determined by immunoprecipitation of 200 mg of total protein with 3 mg of p21 monoclonal antibody (Santa Cruz Biotechology, Santa Cruz, CA, USA). Incubation was at 41C for 1 h, followed by addition of 15 ml of 50% protein A : agarose and incubation overnight with agitation at 41C, followed by centrifugation. The pellet was washed three times with 1 Â immunoprecipitation buffer (1% triton X-100, 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA pH8.0, 0.2 mM sodium orthovanadate, 0.2 mM PMSF and 0.5% NP-40), and resuspended in 30 ml of 2 Â immunoprecipitation sample buffer (250 mM Tris, pH 6.8, 4% SDS, 10% glycerol, 0.06% bromophenol blue and 2% 2-mercaptoethanol). After boiling for 5 min and centrifugation at 14 000 r.p.m. for 5 min at 41C, the supernatant was loaded onto an SDS-PAGE gel and fractionated by electrophoresis, the protein transferred to a nitrocellulose membrane and probed with HRP-conjugated anti-mouse antibody (Santa Cruz Biotechology, Santa Cruz, CA, USA). Signal was detected by the enhanced chemiluminescence technique (Amersham Life Science, Piscataway, NJ, USA). The signal was then quantified using ImageQuant software (Molecular Dynamics) p21 methylation and intestinal tumorigenesis WC Yang et al (not shown), consistent with the continued basal expression of the gene in these mice, albeit at lower levels than in the wild-type mice. We, therefore, turned to analysis of epigenetic mechanisms that might abrogate the induction of p21 in response to sulindac.
Methylation of CpG residues in the promoters of genes can be an effective mechanism for their inactivation (Esteller, 2002; Esteller et al., 2002) . There is precedent that this is a mechanism which functions in intestinal tumorigenesis, especially well-documented for the inactivation of genes involved in DNA mismatch repair (Esteller, 2002) . We, therefore, first determined whether there were CpG 'islands' in the promoter of the mouse p21 gene. Figure 2a illustrates that two regions were identified as CpG 'islands' (Li and Dahiya, 2002; Laird, 2003; Xian et al., 2004) . The region more proximal to the site of transcriptional initiation spanned 319 nucleotides from þ 103 to À216 relative to the 5 0 end of the transcript, encompassing 23 CpG dinucleotides; the region more distal spanned 100 nucleotides from À676 to À775 and encompassed seven CpG dinucleotides. This more distal region is generally smaller, and further upstream of the transcriptional start site, than canonical CpG islands, and might therefore preferably be termed a CpG cluster, although it should be emphasized that there is no agreement regarding what structural features constitute a CpG island and the extent of methylation that is necessary for effects on transcription Rountree et al., 2001; Laird, 2003) . The state of methylation of the cytosine residues in the CpG sequences was determined by bisulfite sequencing (Frommer et al., 1992) .
There was infrequent methylation of the cytosines of CpG sequences in the proximal CpG island of the p21 gene in the duodenal mucosa and in the duodenal tumors of both Apc (Figure 2b ). Moreover, there was no consistency among the differences either between the tissues or the genotypes assayed. The absence of significant methylation in this proximal CpG island is consistent with the continued basal expression of the wild-type p21 allele in the Apc
þ /À mice (Figure 1 ). However, for the distal CpG cluster, markedly different results were obtained (Figure 2b ). For the normal mucosa, methylation was again infrequent for 11 mice of the Apc
þ / þ genotype (11 of 77 potential sites, or 14%), but the extent of methylation was approximately sixfold higher for the mucosa in Apc
þ /À mice (82% of the potential sites). A similar result was obtained for the distal CpG cluster in the tumors: 30% of potential sites were methylated in the tumors of Apc
þ / þ mice, and this increased to 81% in the Apc
þ /À tumors. Therefore, the substantial increase in methylation of the distal CpG cluster in both the mucosa and the tumors of Apc
þ /À mice likely accounts for the fact that p21 is not inducible by sulindac in these tissues in these mice (Figure 1) . Two facts should be noted regarding methylation in the upstream CpG cluster in the mucosa compared to the tumors of Apc
þ / þ orÀ/À mice: first, there is a low level of methylation (14% of potential sites) in the mucosa of Apc (Figure 2b ). This may be linked to microadenomas, as well as aberrant crypt foci, that have formed in the mucosa due to the Apc mutation by the 36-week time point at which the mice were killed (Pretlow et al., 2003) . Therefore, some of the methylated sites in the flat mucosa may in fact be derived from preneoplastic or neoplastic lesions, which are very small and not dissected out prior to isolation of DNA from these tissues. Second, the extent of methylation in the CpG cluster increases in the tumors compared to the mucosa of these Apc
þ / þ mice (30% in tumors compared to 14% in mucosa), consistent with an approximately 30% decrease in expression of the gene in the tumors compared to the mucosa (P ¼ 0.05, Figure 3) . The relationship between methylation of CpG sites of this cluster and expression of the gene (assayed by quantitative RT-PCR) in the 'normal' mucosa and tumors of Apc
mice is also shown in Figure 3 . For these normal and tumor tissues and genotypes (N of 6 per group), there is a highly significant inverse correlation between extent of methylation and expression of the gene (P ¼ 0.02), again consistent with an important role for methylation in this region in control of expression of the mouse p21 gene. However, we also point out that the promoter of the human p21 gene has been shown to respond positively and negatively to a great number of signals, involving many different cis-acting elements along at least 4 kB upstream of the transcriptional start site (Gartel and Tyner, 1999) , suggesting that the status of p21 methylation in this upstream CpG cluster of the mouse gene may be only one factor in integrated regulation of the gene.
In addition to the large increase in overall methylation of the distal CpG cluster in the tissues from the Apc
þ /À mice, there are sites of particular interest. This is summarized in Figure 4 . Highest methylation of the wild-type p21 allele in Apc þ /À , p21 þ /À mice is at positions 4 and 5, which are nearly 100% methylated in the normal and tumor tissue, respectively. However, the greatest differential in methylation between the p21 genotypes is at positions 1 and 2, which are virtually never methylated in the Apc
þ / þ tissues. The relationship between the methylation of these sites and cis-acting elements that regulate response of the mouse p21 promoter to sulindac, and NSAIDs in general, remains to be determined.
Promoter hypermethylation is often an early event in tumor progression Jones and Baylin, 2002) . The earliest stage appears to involve genes where promoter region hypermethylation increases in normal tissue as a function of aging. In fact, in the colon, the genes with the highest incidence of promoter hypermethylation in tumors fall into this category, and the age-related curves for the increase in hypermethylation and risk of colon cancer are remarkably similar . In our studies, the canonical CpG island remained unmethylated in the mucosa and tumors of Apc þ /À , p21 þ /À mice, consistent with the continued basal expression of p21 in these tissues. However, hypermethylation of the distal p21 WAF1 promoter. Genomic DNA was isolated using a DNeasy Tissue Kit (Qiagen, Valencia, CA, USA) from the flat mucosa of small intestine, or from intestinal tumor cells microdissected by laser capture (LCM) using an Arctur Pix 100 system (Mountain View, CA, USA). Cytosine methylation was determined using bisulfite sequencing as described (Frommer et al., 1992) , with modification. Briefly, DNA (up to 2 mg) was diluted into 50 ml with distilled water and incubated with 3.7 ml of 3 M NaOH at 371C for 10 min to create single-stranded DNA. Then 15 ml of freshly prepared 10 mM hydroquinone was added to each tube followed by 260 ml of fresh 3 M sodium bisulfite, with the pH adjusted to 5.0 with NaOH. The reaction was incubated at 501C for 18 h. Under these conditions, unmethylated cytosine was converted to uracil, but 5 0 -methylcytosine remained as cytosine. Modified DNA was purified with a Qiagen Gel Extraction Kit. NaOH was added to the modified DNA (final concentration 0.3 M), which was then incubated for 10 min at room temperature for desulfonation. A Qiagen Gel extraction kit was again used to purify the modified DNA. Modified DNA was assayed immediately or stored at À201C. There are two CpG 'islands', as identified by MethPrimer Software (Li and Dahiya, 2002; Laird, 2003; Xian et al., 2004) in the promoter region of the mouse p21 gene (Locus MMU24171) (a). The primers for methylation-specific PCR were designed using MethPrimer. As shown in (a), the primers for the distal CpG cluster (100 bp, from À775 to À676) were: forward (À824 to À800) -5 0 -TGGTTTGAGAATTGGATTTAATTTT-3 0 ; reverse (À641 to À665) -5 0 -TCCCAAAAAATCCCACTATATCTAA-3 0 . The primers for the proximal CpG island (319 bp, from À216 to þ 103) were: forward (À209 to À183) -5 0 -TGATAAGAGAATAGTTTAGGTGTGGG-3 0 , reverse ( þ 99 to þ 123) -5 0 -AAAAAAAACTATTATTCCCTACCAC-3 0 . The thermal cycler was programmed as follows: denaturation at 951C for 5 min, followed by 35 cycles of denaturation at 951C for 45 s, annealing at 561C for 45 s and extension at 721C for 45 s, and then 721C for 10 min at completion. The amplified fragment for the distal region is 184 bp, which encompasses the seven CpG sequences in this region. The amplified fragment for the proximal region is 331 bp, which encompasses the 23 CpGs in the promoter and part of exon 1. The PCR products were fractionated by electrophoresis on a 1.3% agarose gel, extracted, and cloned into a pCR-4 vector using the TOPO-TA Cloning Kit (Invitrogen Life Technology, Carlsbad, CA, USA). Plasmid DNA was isolated with the MiniPrep Kit (Qiagen, Valencia, CA, USA). The insert was confirmed by EcoRI digestion and fractionation on a 1.3% agarose gel. The identified plasmid DNA was sequenced by the Albert Einstein Core DNA sequencing facility using an ABI 3700 PRISM DNA Analyzer (Applied Biosystem Inc., CA, USA). At least three subclones from each sample were screened. A position was scored as methylated for a sample if the majority of subclones (e.g. 2/3 or 3/5) indicated methylation. This methodology is standard and highly sensitive for determining methylation status of a defined locus cluster in the promoter likely happened in the early stage in the Apc
þ /À mice, since it is apparent in the flat, normal appearing mucosa of these animals. Moreover, we did not detect any difference in this hypermethylation in the mice fed sulindac (data not shown). Therefore, unlike the chemotherapeutic drug 5 0 -aza-2 0 deoxycytidine (Christman, 2002; Pohlmann et al., 2002; Lavelle et al., 2003; Zhu et al., 2004 ) (a compound related to azacytidine) or the chemopreventive nutrient selenium (Davis and Uthus, 2003), sulindac does not have the ability to cause demethylation of the cytosine residues in CpG sequences, and hence is not able to restore the ability of p21 to be induced.
Despite the fact that p21 plays an important role in intestinal cell maturation, including cessation of cell proliferation and lineage specific differentiation, it is surprising that mice, even with homozygous inactivation of the locus, have a grossly normal mucosa and require introduction of an initiating mutation in Apc to exhibit tumor formation (Fodde et al., 1994; Deng et al., 1995; Yang et al., 2001a, b) . This is in contrast to mice that are heterozygous or homozygous for inactivation of another cdk inhibitor, p27 kip1 , in which we have found that tumors form strictly as a function of diet without introduction of an Apc mutation (Yang et al., 2003, unpublished) . Thus, p21 inactivation exerts a different phenotype when Apc is inactivated compared to when Apc is wild type. It is possible that the altered methylation of the distal CpG cluster of the p21 promoter is in fact dependent upon altered Apc function. Further, although p21 is not generally hypermethylated in human colon cancer (Kondo et al., 2003 (Kondo et al., , 2004 , it will be important to determine if methylation of specific sites in the p21 promoter takes place in a subset of human colon cancer, if this is linked to decrease or loss of APC function, and if this is a prognostic factor in response of patients to NSAID treatment. The data presented here also imply that combination treatment with sulindac and an agent which promotes demethylation may be particularly beneficial in either therapy or prevention. Figure 1 ) and extent of methylation of C residues in the distal CpG cluster (see Figure 2) for the duodenal mucosa and tumors of mice that are Apc þ /À , p21 
